Watch the full video on Radcliffe Cardiology here: [ Ссылка ]
In this short interview, Dr Rafael Romaguera (University of Barcelona, SP) discusses the findings from the SUGAR trial. This randomized head-to-head trial aimed to compare Cre8 EVO stents to a contemporary drug-eluting stent (DES) in patients with diabetes (DM) and coronary artery disease. The trial, first presented at TCT 2021, demonstrated that Cre8 EVO stents were non-inferior to Resolute Onyx stents with regards to TLF composite outcome.
Discussion Points:
- Amphilimus Coating
- Importance of the Trial
- Design and Patient Population
- Key Findings
- Impact of Practice
- Next Steps
Recorded remotely from Barcelona, 2021.
Editor: Mirjam Boros
Radcliffe Cardiology is a dynamic, digitally-focused producer & publisher of Cardiovascular, Renal and Metabolic (CVRM) content for physicians worldwide. We aim to assist in the continuous education of physicians within the cardiology fraternity, generating a range of clinical content through collaboration with leading cardiologists from around the globe.
